Federal Scientist: Pull Avandia From the Market Because of Heart Risks

Avandia should be pulled from the market because of heart risks, said a federal scientist, according to an article in the Associated Press.

Those risks, combined with no unique short-term benefits in helping diabetics control blood-sugar levels, fail to justify keeping Avandia on the market, according to a copy of a slide presentation by Food and Drug Administration scientist Dr. David Graham.

The document was distributed at the onset of a daylong meeting of a joint panel of outside experts convened to consider whether the drug should be restricted to use in select patients and branded with prominent warnings or removed altogether from sale.

Glaxo says its own data show no increase in heart risks with Avandia compared with other diabetes drugs, including Actos.

If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney. Get a free case review by filling out the form below.

Click To Talk To Us Online

see also:

Veterans Affairs: Avandia Veterans Affairs Severely Limits Use of GlaxoSmithKline's Avandia Drug
Veterans Affairs Limits Use of Glaxo's Avandia Due to Safety Concerns

Patients Switch Meds Physicians Take Patients off Avandia Medicine, Citing its Heart Risks
Fearing the Cardiovascular Risks, Doctors Take Patients off Avandia

News & Warnings Avandia News and Information | Weitz & Luxenberg
Bloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001